{"id":5005,"date":"2014-10-25T12:14:58","date_gmt":"2014-10-25T12:14:58","guid":{"rendered":"\/?p=5005"},"modified":"2014-10-25T12:15:03","modified_gmt":"2014-10-25T12:15:03","slug":"cellceutix-corp-otcmktsctix-advances-to-a-new-52-week-high","status":"publish","type":"post","link":"\/articles\/cellceutix-corp-otcmktsctix-advances-to-a-new-52-week-high\/","title":{"rendered":"Cellceutix Corp (OTCMKTS:CTIX) Advances to a New 52-Week High"},"content":{"rendered":"\n<p><img loading=\"lazy\" decoding=\"async\" style=\"float: right;\" src=\"\/\/s.hotstocked.com\/hotstocked.com\/repository\/articles\/88\/88355\/ctix_chart.png\" border=\"0\" width=\"532\" height=\"237\" \/>Cellceutix Corp (OTCMKTS:<a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a>) may have broken its positive streak on Wednesday, but yesterday it more than made up for the 0.33% dip. The stock racked up quite the volume &ndash; 1.6 million shares, with a trade value of over $5 million, and surged 6.33%. <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>hit a new 52-week high closing at $3.19. <\/p>\n<p>The stock&#8217;s ascend should come as no surprise, as the company issued a press release yesterday. The PR disclosed some good news about the top-line results for the Phase 2b clinical ABSSSI trials. The trials began in February and <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>announced that they are positive. According to the PR, due to this data <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>has decided to begin Phase 3 ABSSSI trials in 2015. The company fails to specify when in 2015 exactly, so hopefully for investors, their next quarterly will shed some light on the matter.<\/p>\n<p><iframe loading=\"lazy\" style=\"float: right;\" src=\"http:\/\/www.youtube.com\/embed\/VEN-4V9KuHo\" width=\"425\" height=\"350\"><\/iframe><\/p>\n<p>The release also announced <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a><\/strong>&#8216;s intentions of taking part in a conference held in Denmark on April 25, 2015. There the company will give a presentation on the aforementioned Phase 2b clinical trials.<\/p>\n<p>Until <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>files its next 10-Q, let&#8217;s take a look at their latest available report &ndash; their 10-K. It covers the fiscal year ended June 30 and it shows numbers typical for clinical stage pharma companies. They showed substantial net loss and working capital deficit, and naturally, no revenues.<\/p>\n<p>What potential investors should keep in mind is that the products <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>is currently developing <em>&ldquo;are not likely to be commercially available for several years&rdquo;.<\/em> What&#8217;s more <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a> <\/strong>doesn&#8217;t expect to <em>&ldquo;complete the development of a product candidate for several years, if ever&rdquo;<\/em>. For investors these statements mean that they will have to get used to seeing similar figures in <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a><\/strong>&#8216;s coming reports, since they are unlikely to change any time soon.<\/p>\n<p>Investors should familiarize themselves thoroughly with the details surrounding <strong><a href=\"http:\/\/www.thehotpennystocks.com\/Stock-Quotes\/?stock=CTIX\">CTIX<\/a><\/strong>, before deciding whether or not to commit to its stock.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cellceutix Corp (OTCMKTS:CTIX) may have broken its positive streak on Wednesday, but yesterday it more than made up for the 0.33% dip. The stock racked up quite the volume &ndash; 1.6 million shares, with&#46;&#46;&#46;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[730],"class_list":["post-5005","post","type-post","status-publish","format-standard","hentry","category-news","tag-ctix"],"_links":{"self":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/5005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/comments?post=5005"}],"version-history":[{"count":0,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/5005\/revisions"}],"wp:attachment":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/media?parent=5005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/categories?post=5005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/tags?post=5005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}